Characterization of enzymes responsible for biotransformation of the new antileukotrienic drug quinlukast in rat liver microsomes and in primary cultures of rat hepatocytes

Journal of Pharmacy and Pharmacology

Volumn 56, Issue 2, 2004, Pages 205-212

  Szotáková, Barbora ^a   Skálová, Lenka ^a   Baliharová, Vendula ^a   Dvorsčáková, Martina ^a   Štorkánová, Lenka ^a   Šišpera, Luděk ^a   Wsól, Vladimír ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 3A; DEXAMETHASONE; DRUG METABOLITE; ETHOXYRESORUFIN; KETOCONAZOLE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METYRAPONE; MONTELUKAST; PRANLUKAST; PYRAZOLE DERIVATIVE; QUINLUKAST; UNCLASSIFIED DRUG; VERLUKAST; VUFB 19363; ZAFIRLUKAST;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME INDUCTION; ENZYME INHIBITION; IN VITRO STUDY; INCUBATION TIME; LIVER CELL CULTURE; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; PHARMACOKINETICS; RAT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CELL SURVIVAL; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; ENZYME INDUCTION; HEPATOCYTES; ISOENZYMES; LEUKOTRIENE ANTAGONISTS; MALE; MICROSOMES, LIVER; OXYGENASES; QUINOLINES; RATS; RATS, WISTAR; SULFOXIDES;

EID: 1242331424     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357023060     Document Type: Article

References (31)

1. Balani, S. K., Xu, X., Pratha, V., Koss, M. A., Amin, R. D., Dufresne, C., Miller, R. R., Arison, B. H., Doss, G. A., Chiba, M., Freeman, A., Holland, S. D., Schwartz, J. I., Lasseter, K. C., Gertz, B. J., Isenberg, J. I., Rogers, J. D., Lin, J. H., Baillic, T. A. (1997) Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotrienel recepror antagonist, in human plasma and bile. Drug Metab. Dispos. 25: 1282-1287
2. Berry, M. N., Edwards, A. M., Barritt, G. J. (1991) Isolated hepatocytes - preparation, properties and applications. In: van der Vliet, P. C., Pillai, S. (eds) Laborotory techniques in biochemistry and molecular, biology. Elsevier Science, Amsterdam, pp 1-470
3. Burke, M. D., Thompson, S., Elcombe, C. R., Halpert, J., Haaparanta, T., Mayer, R. T. (1985) Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochem. Pharmacol. 34: 3337-3345
4. Burke, M. D., Thompson, S., Weaver, R. J., Wolf, C. R., Mayer, R. T. (1994) Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem. Pharmacol. 48: 923-936
5. Chiba, M., Xu, X., Nishime, J. A., Balani, S. K., Lin, J. H. (1997) Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab. Dispos. 25: 1022-1031
6. Chung, K. F., Barnes, P. J. (1998) Zafirlukast (Accolate TM). Drugs Today 34: 375-388
7. Dekhuijzen, P. N., Koopmans, P. P. (2002) Pharmacokinetic profile of zafirlukast. Clin. Pharmacokinet. 41: 105-114
8. Denizat, F., Lang, R. (1986) Rapid colorimetric assay for cell growth and survival. J. Immunol. Methods 89: 271-277
9. Gillette, J. R. (1971) Techniques for studying drug metabolism in vitro. In: La Du, B. N., Mandel, H. G., Way, E. L. (eds) Fundamentals of drug metabolism and drug disposition. The Williams and Wilkins Company. Baltimore, pp 400-418
10. Grossman, S. J., Herold, E. G., Drey, J. M., Alberts, D. W., Umbenhauer, D. R., Patrick, D. H., Nicoll-Griffith, D., Chauret, N., Yergey, J. A. (1993) CYP1A1 specificity of verlukast epoxidation in mice, rats, rhesus monkeys, and humans. Drug. Metab. Dispos. 21: 1029-1036
11. Isom, H. C., Georgoff, I. (1984) Quantitative assay for albumin-producing liver cell after simian virus transformation of rat hepatocytes maintained in chemically defined medium. Proc. Natl Acad. Sci. U S A 8: 6378-6382
12. Jain, N. K., Kulkarni, S. K., Singh, A. (2001) Role of cysteinyl leukotrienes in nociceptive and inflammatory conditions in experimental animals. Eur. J. Pharmacol. 421: 85-92
13. Kirchar, M., Culikova, K., Panajotovova, V., Brunova, B., Jandera, A., Kmonicek, K., (1998) 2,4-Dihydroxyacetophenone derivatives as antileukotrienics with a multiple activity mechanism. Collect. Czech. Chem. Commun. 63: 103-114
14. Kuchar, M., Brunova, B., Panajotova, V., Jandera, A. (2000) The derivatives of arylsulfanyl benioic acids with multiple antileukotrienic activities. 11th International Conference Advances in Prostaglandin and Leukotriene Research, Florence, June 2000, Abstract Book, p. 82
15. Kuchar, M., Kmonicek, V., Panajotova, V., Brunova, B., Jandera, A., Jirickova, H., Bucharova, V. (2001) Derivatives of hydroxyphenylsulphanylbenzoic and hydroxyphenylsulphanylarylacetic acids. U.S. 6,303,612 B1
16. Kuchar, M., Kmonicek, V., Panajotova, V., Jandera, A., Brunova, B., Junek, R., Bucharova, V., Cejka, J., Satinsky, D. (2004) Derivatives of phenylsulfanyl benzoic acids with multiple antileukotrienic activity. Collect. Czech. Chem. Commun. In Press
17. Lu, C., Li, A. P. (2001) Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Cem. Biol. Interact. 134: 271-281
18. Markwell, M. A., Haas, S. M., Bieber, L. L., Tolbert, N. E. (1978) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87: 206-210
19. Maurel, P. (1996) The use of adult human hepatocytes in primary culture and other in vitro systems to investigate drug metabolism in man. Adv. Drug Deliv. Rev. 22: 105-132
20. Nelson, D. R., Kamataki, T., Waxman, D. J., Guengerich, F. P., Estabrook, R. W., Feyereisen, R., Gonzalez, F. J., Coon, M. J., Gunsalus, I. C., Gotoh, O. (1993) The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 12: 1-51
21. Nicoll-Griffith, D. A., Channel, N., Yergey, J. A., Trimble, L. A., Favreau, L., Zamboni, R., Grossman, S. J., Drey, J., Herold, E. (1993) Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1). Drug Metab. Dispos. 21: 861-867
22. Parkinson, A. (2001) Biotransformation of xenobioties. In. Klaassen, C. D. (ed.) Caserett and Doull's toxicology. In: basic science of poisons. 6th edn, McGraw-Hill Companies, Inc., pp 133-224
23. Radhakrishna, T., Satyanarayana, J., Satyanarayana, A. (2002) Determination of zafirlukast by stability indicating LC and derivative spectrophotometry. J. Pharm. Biomed. Anal. 30: 695-703
24. Ravasi, S., Capra, V., Panigalli, T., Rovati, G. E., Nicosia, S. (2002) Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem. Pharmacol. 63: 1537-1546
25. Savidge, R. D., Bui, K. H., Birmingham, B. K., Morse, J. L., Spreen, R. G (1998) Metabolism and excretion of zafirlukast in dogs, rats, and mice. Drug Metab. Dispos. 26: 1069-1076
26. Testa, B. (1995) The nature and functioning of cytochromes P450 and Flavin-containing-monooxygenases. In: Testa, B., Caldwell, J. (eds) The metabolism of drugs and other xenobiotics. Biochemistry of redox reactions. Academic Press, Harcourt Brace and Company, Publishers, London, pp 70-121
27. Vianna, E. O., Martin, R. J. (1998) Recent innovations in asthma therapy. Drugs Today 34: 341-351
28. Weisberg, S. C. (2000) Pharmacotherapy of asthma in children with special reference to leukotriene receptor antagonists. Pediatr. Pulmonol. 29: 46-61
29. Wsól, V., Szotakova, B., Baliharova, V., Sispera, L., Holcapek, M., Kolarova, L., Suchanova, B., Kuchar, M., Skalova, L. (2004) The phase I biotransformation of the potential antileukotrienic drug quinlukast in rat in vitro. Collect. Czech. Chem. Commun. In press
30. Ziegler, D. M. (1990) Flavin-containing monooxygenases: enzymes adapted for multisubstrate specificity. Trends Pharmacol. Sci. 11: 321-324
31. Ziegler, D. M. (1993) Recent studies on the structure and function of multisubstrate flavin-containing monooxygenases. Annu. Rev. Pharmacol. Toxicol. 33: 179-99